Abstract 3444: The Effect of Alpha Lipoic Acid on Porcine Coronary Stent Restenosis

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Myung Ho Jeong ◽  
Eun Hui Bae ◽  
Sang Yup Lim ◽  
Jae Youn Moon ◽  
Ju Han Kim ◽  
...  
Keyword(s):  
Coronary Arteries ◽  
Lipoic Acid ◽  
Bare Metal Stents ◽  
Metal Stents ◽  
Control Group ◽  
List Type ◽  
Bare Metal ◽  
Alpha Lipoic Acid ◽  
Stent Group ◽  
Injury Score

Objective: We evaluated the ability of alpha lipoic acid (ALA) to affect on coronary instent restenosis (ISR) in a porcine model. Methods: In vitro experiment: We stimulated porcine VSMC using G-CSF in the presence or absence of ALA. Activation of Akt, vascular endothelial growth factor (VEGF), extracellular signal-regulated kinase (ERK) and signal transducer and activator of transcription (STAT)-3 were determined using western blot. And also, cell proliferation and migration assay were determined. In vivo experiment:Balloon overdilation injuries were performed in 2 coronary arteries in 12 pigs. Four weeks after the balloon overdilation injury, 24 bare metal stents were placed for 24 injured coronary arteries. We randomized into two groups (12 stents per group; control group: aspirin and clopidogrel only, ALA group: aspirin and clopidogrel plus 100 mg/kg ALA during 4 weeks). 16 bare metal stents were implanted randomized two coronary arteries in 8 pigs. Group I was control stent group (n=8), Group II was ALA coated stent group (n=8). Follow-up coronary angiogram (CAG) and histopathologic assessment were performed at 4 weeks after stenting. Results: G-CSF increased the phosphorylation of ERK and STAT-3, but after pretreatment of ALA, the phosphorylation of ERK and STAT-3 were significantly reduced. On histopathologic analysis, injury score, internal elastic lamina(IEL) area did not differ significantly between the two groups. The neointimal area was 7.3±0.9 mm2 in control group and 2.2±1.1 mm2 in ALA group (p<0.001), and the histopathologic area of stenosis(AS) was 75.9±8.5 % in control group, 23.5±10.5 % in ALA group (p<0.001). The injury score and IEL area were not significantly different between the two groups. The neointimal area was 7.4±1.1 mm2 in control group and 1.4±0.8 mm2 in ALA group (p<0.001), and the AS was 77.6±10.9 % in control group, 15.6±7.6 % in ALA group (p<0.001). The number of inflammatory cells within neointima was lower in ALA group (63.2±23.7 % vs. 17.6±11.6 %, p<0.001). Conclusion: ALA inhibits the activation of ERK, STAT-3 and proliferation of VSMC. Both high dose of oral ALA and ALA coated stents inhibit neointimal hyperplasia in a porcine ISR model

Bare metal stents can maintain arterial patency in traumatic occlusion

2018 ◽  
Vol 2 (1) ◽  
Author(s):  
Viktor A Reva ◽  
Jonathan J Morrison ◽  
Alexey V Denisov ◽  
Alexey B Seleznev ◽  
Gennady G Rodionov ◽  
...  
Keyword(s):  
Bare Metal Stents ◽  
Bare Metal Stent ◽  
Metal Stents ◽  
Control Group ◽  
Bare Metal ◽  
Metal Stent ◽  
Ovine Model ◽  
Stent Group ◽  
Stent Deployment ◽  
Arterial Patency

Background: The standard approach to an occlusive vascular injury is open arterial reconstruction, although endovascular stenting is becoming more common, despite limited evidence. The aim of this study is to examine the performance of bare-metal stents in an ovine model of occlusive arterial trauma. Methods: Through a groin incision, a 2 cm segment of the left superficial femoral artery (SFA) was bluntly injured using a hemostat and injection of air to achieve thrombosis. Animals then underwent a stent deployment (Stent group, n=5) or no-treatment (Control group, n=5). In the Stent group, recanalization of the thrombotic lesion, thromboaspiration and bare-metal stent deployment were performed. Enoxaparin 1.5 mg/kg was given to all animals. The stent group animals were fed Clopidogrel 75 mg and Aspirin 125 mg daily. Angiography and doppler ultrasound were used to evaluate arterial patency during the 7-day observation period. Results: A thrombosis was obtained in all cases. After the fall in the systolic velocity (SV, cm/sec) in both the Control (43 (36–56) to 6 (0–16); p<0.001) and Stent Groups (45 (32–53) to 8 (0–12); p<0.001), stent implantation resulted in a significant permanent increase of the SV. Day 7 angiography confirmed SFA patency in all (5/5) stented animals, with persisting occlusions in the Control group (p=0.008). There was no evidence of distal emboli in the run-off arteries. Conclusions: Bare-metal stent implantation restores arterial patency of a traumatic occlusive lesion in a standardized ovine model with a short follow-up period.

scholarly journals Bare Metal Stents on Resveratrol-Coated Balloons in Porcine Coronary and Peripheral Arteries

2021 ◽  
Vol 22 (23) ◽  
pp. 13099
Author(s):  
Stefanie Kamann ◽  
Tobias Haase ◽  
Nicola Stolzenburg ◽  
Melanie Löchel ◽  
Daniel Peters-Berg ◽  
...  
Keyword(s):  
Coronary Arteries ◽  
Bare Metal Stents ◽  
Vasa Vasorum ◽  
Metal Stents ◽  
Control Group ◽  
Bare Metal ◽  
Peripheral Arteries ◽  
Beneficial Effects ◽  
Positive Effects ◽  
Resveratrol Treatment

Balloon angioplasty and stent implantation are standard techniques to reopen stenotic vessels. Often, balloons or stents coated with cytostatic drugs are used to prevent re-occlusion of the arteries. Resveratrol, which is known for its numerous beneficial effects on cardiovascular health, is used as an antioxidant additive on paclitaxel-coated balloon catheters. What is still unclear is whether resveratrol-only balloon coating in combination with a bare metal stent (BMS) also has positive effects on vascular healing. Here, we analyzed neointimal thickening, fibrin deposition, inflammation, vasa vasorum density, and reendothelialization after implantation of BMS via a resveratrol coated balloon approach in a porcine model. In general, resveratrol treatment did not result in significantly altered responses compared to the control group in peripheral arteries. In coronary arteries, an increase in vasa vasorum density became evident three days after resveratrol treatment compared to the control group and abolished up to day 7. Significant effects of the resveratrol treatment on the fibrin score or intima-media area were transient and restricted to either peripheral or coronary arteries. In conclusion, local single-dose resveratrol treatment via a resveratrol-only coated balloon and BMS approach did not lead to adverse systemic or local effects, but also no significant beneficial effects on vascular healing were detected in the current study.

scholarly journals Extended Follow-Up by Serial Angioscopic Observation for Bare-Metal Stents in Native Coronary Arteries

2009 ◽  
Vol 2 (3) ◽  
pp. 205-212 ◽  
Author(s):  
Shinya Yokoyama ◽  
Masamichi Takano ◽  
Masanori Yamamoto ◽  
Shigenobu Inami ◽  
Shunta Sakai ◽  
...  
Keyword(s):  
Coronary Arteries ◽  
Bare Metal Stents ◽  
Metal Stents ◽  
Bare Metal

scholarly journals Do ultrathin strut bare-metal stents with passive coating improve efficacy in large coronary arteries? Insights from the randomized, multicenter BASKET-PROVE trials

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Kim Wadt Hansen ◽  
Raban Jeger ◽  
Rikke Sørensen ◽  
Christoph Kaiser ◽  
Matthias Pfisterer ◽  
...  
Keyword(s):  
Silicon Carbide ◽  
Coronary Arteries ◽  
Cardiac Death ◽  
Proportional Hazards ◽  
Bare Metal Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Cobalt Chromium ◽  
Stent Type ◽  
Large Coronary Arteries

Abstract Background The new generation thinner-strut silicon carbide (SiC) coated cobalt chromium (CoCr) bare-metal stents (BMS) are designed to accelerate rapid endothelialisation and reduce thrombogenicity when implanted in coronary arteries. However, smaller studies suggest higher rates of symptomatic restenosis in patients receiving the newer generation BMS. We investigated the efficacy of a newer generation ultrathin strut silicon-carbide coated cobalt-chromium (CoCr) BMS (SCC-BMS) as compared to an older thin-strut uncoated CoCr BMS (UC-BMS) in patients presenting with coronary artery disease requiring stenting of large vessels (≥3.0 mm). Methods All patients randomized to SCC- (n = 761) or UC-BMS (n = 765) in the two BASKET-PROVE trials were included. Design, patients, interventions and follow-up were similar between trials except differing regimens of dual antiplatelet therapy. The primary endpoint was clinically driven target-vessel revascularization within 24 months. Safety endpoints of cardiac death, non-fatal myocardial infarction (MI), and definite/probable stent thrombosis (ST) were also assessed. We used inverse probability weighted proportional hazards Cox regressions adjusting for known confounders. Results Demographics, clinical presentation, and risk factors were comparable between the groups, but patients receiving SCC-BMS underwent less complex procedures. The risk for clinically driven TVR was increased om the SCC-BMS group compared to the UC-BMS group (cumulative incidence, 10.6% vs. 8.4%; adjusted relative hazard [HR], 1.49 [95% CI, 1.05–2.10]). No differences in safety endpoints were detected, cardiac death (1.6% vs. 2.8%; HR, 0.62 [CI, 0.30–1.27]), non-fatal MI (3.2% vs. 2.5%; HR, 1.56 [CI, 0.83–2.91]), and definite/probable ST (0.8% vs. 1.1%; HR, 1.17 [CI, 0.39–3.50]). Differences in strut thickness between the two stents did not explain the association between stent type and clinically driven TVR. Conclusions In patients requiring stenting of large coronary arteries, use of the newer generation SCC-BMS was associated with a higher risk of clinically driven repeat revascularization compared to the UC-BMS with no signs of an offsetting safety benefit.

Sign in / Sign up

Export Citation Format

Share Document